Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation with principal executive offices in Australia, filed this Form 8-K on July 30, 2025, reporting events occurring on July 25, 2025. The filing details the entry into a material definitive agreement involving the issuance of a convertible promissory note.
Key Financial Metrics
- Debt Issuance: The Company issued a convertible promissory note with an aggregate principal amount of $112,350.
- Proceeds: The purchase price received was $107,000.
- Interest Rate: The note bears interest at 22% per annum.
- Maturity Date: April 30, 2026.
- Use of Proceeds: General working capital purposes.
- Liquidity Impact: The filing does not provide current cash balances or liquidity ratios; it only confirms the receipt of $107,000 in proceeds.
Material Changes and Terms
The primary material change is the creation of a new direct financial obligation. Key terms of the note include:
- Conversion Terms: Convertible into common stock at the investor's option after 180 days. The conversion price is 75% of the average lowest trading price during the 10 trading days prior to conversion (a 25% discount).
- Prepayment Rights: The Company may prepay within the first 90 days at a 120% premium. Between 90 and 180 days, the premium increases to 125%. No prepayment right exists after 180 days.
- Reserve Requirement: The Company must maintain a reserve of at least five times the number of potential conversion shares.
- Ownership Limitation: Conversions are subject to a 4.99% beneficial ownership limitation.
Outlook, Risks, and Contingencies
Management intends to use the proceeds for general working capital. The filing highlights several risks and contingencies associated with the note:
- Events of Default: Include failure to pay principal/interest, failure to issue conversion shares, failure to maintain OTC market listing, failure to comply with SEC reporting requirements, insolvency, or bankruptcy.
- Acceleration: Upon an event of default, the note becomes immediately due and payable.
- Dilution Risk: The 25% discount on conversion and the requirement to maintain a 5x share reserve may lead to significant dilution of existing shareholders.
- Regulatory Status: The securities were issued pursuant to the private placement exemption under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the Company's current cash position to assess the necessity of high-interest financing (22% rate).
- Review the Company's ability to maintain its OTC market listing, as failure to do so constitutes an event of default.
- Assess the potential dilution impact by calculating the maximum number of shares issuable under the 5x reserve requirement.
- Confirm the Company's compliance with ongoing SEC reporting requirements to avoid triggering default clauses.
- Examine the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 4.1) for additional covenants not summarized in the 8-K.